PMC:7534795 / 58167-59057
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T235 | 318-326 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T408 | 139-147 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T409 | 817-825 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T348 | 28-33 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T180 | 28-33 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T60396 | 93-98 | Chemical | denotes | PUFAs | http://purl.obolibrary.org/obo/CHEBI_26208 |
| T23982 | 232-237 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T29687 | 314-317 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364 |
| T96930 | 405-408 | Chemical | denotes | EPA | http://purl.obolibrary.org/obo/CHEBI_28364 |
| T15357 | 442-448 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T186 | 488-490 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T65020 | 721-727 | Chemical | denotes | lipids | http://purl.obolibrary.org/obo/CHEBI_18059 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T454 | 0-184 | Sentence | denotes | Currently, there is an open-label, randomized control study to investigate the effect of n-3 PUFAs in hospitalized subjects with confirmed SARS-CoV-2 (NCT04335032) (NCT04335032, 2020). |
| T455 | 185-327 | Sentence | denotes | The study comprises 240 participants, with one group receiving standard care, the other additionally being provided 2 g daily of EPA capsules. |
| T456 | 328-597 | Sentence | denotes | Interventions will be carried out between 28 and 90 days and the efficacy of EPA in the treatment of the disease, oxygen saturation, levels of pro-inflammatory IL-6, mortality rate, ICU stays, hospitalization days and need for mechanical ventilation will be determined. |
| T457 | 598-839 | Sentence | denotes | While the results from this study are not available, the evidence suggests oral or intravenous administration of bioactive lipids could potentially reduce the severity and/or enhance the recovery of those infected with COVID-19 (Das, 2020a). |
| T458 | 840-890 | Sentence | denotes | However, further research is undoubtedly required. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1755 | 488-492 | Gene | denotes | IL-6 | Gene:3569 |
| 1756 | 139-149 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1757 | 209-221 | Species | denotes | participants | Tax:9606 |
| 1758 | 89-98 | Chemical | denotes | n-3 PUFAs | MESH:D015525 |
| 1759 | 314-317 | Chemical | denotes | EPA | MESH:D015118 |
| 1760 | 405-408 | Chemical | denotes | EPA | MESH:D015118 |
| 1761 | 442-448 | Chemical | denotes | oxygen | MESH:D010100 |
| 1762 | 721-727 | Chemical | denotes | lipids | MESH:D008055 |
| 1763 | 494-503 | Disease | denotes | mortality | MESH:D003643 |
| 1764 | 803-811 | Disease | denotes | infected | MESH:D007239 |
| 1765 | 817-825 | Disease | denotes | COVID-19 | MESH:C000657245 |